The Laryngoscope · 2025
Long-Term Daytime Use of Sodium Oxybate in Laryngeal Dystonia: A Follow-Up Online Survey Study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
O'Flynn Lena C, Simonyan Kristina
Аннотация
BACKGROUND: Laryngeal dystonia (LD) is a task-specific focal dystonia marked by involuntary spasms in the laryngeal muscles during speech production. Sodium oxybate has recently been demonstrated as a new treatment option for alcohol-responsive (EtOH+) LD patients.
OBJECTIVE: The objective of this study is to evaluate the long-term use of sodium oxybate for the treatment of LD.
METHODS: A total of 149 LD patients were invited to complete the online survey study. Seventy-seven patients (mean age 65.2 ± 11.5 years, 54 females/23 males) completed 21 questions related to their disorder and the use of sodium oxybate.
RESULTS: Six patients (7.8%) reported receiving a prescription of sodium oxybate for the treatment of their voice symptoms. Of these, three EtOH+ patients (50%) reported receiving 1-1.25 g of sodium oxybate on an as-needed basis, with an average of 79.3% ± 20.0% reduction in self-perceived voice symptoms following drug intake. Drug usage ranged from three times per day 5 days per week to three times per month over the span of 6 months-12 years. Patients reported experiencing mild side effects that lasted 1-2 h, including drowsiness, dizziness, or nausea. The remaining three patients reported not being able to fill their prescriptions due to medical insurance reimbursements.
CONCLUSIONS: Despite the limited sample size, this study demonstrates that the long-term daytime use of sodium oxybate for the treatment of voice symptoms is safe and effective for EtOH+ isolated focal LD patients. The study highlights medical insurance coverage as one of the limiting factors hindering LD patients from accessing this medication.
LEVEL OF EVIDENCE: Level 4.
OBJECTIVE: The objective of this study is to evaluate the long-term use of sodium oxybate for the treatment of LD.
METHODS: A total of 149 LD patients were invited to complete the online survey study. Seventy-seven patients (mean age 65.2 ± 11.5 years, 54 females/23 males) completed 21 questions related to their disorder and the use of sodium oxybate.
RESULTS: Six patients (7.8%) reported receiving a prescription of sodium oxybate for the treatment of their voice symptoms. Of these, three EtOH+ patients (50%) reported receiving 1-1.25 g of sodium oxybate on an as-needed basis, with an average of 79.3% ± 20.0% reduction in self-perceived voice symptoms following drug intake. Drug usage ranged from three times per day 5 days per week to three times per month over the span of 6 months-12 years. Patients reported experiencing mild side effects that lasted 1-2 h, including drowsiness, dizziness, or nausea. The remaining three patients reported not being able to fill their prescriptions due to medical insurance reimbursements.
CONCLUSIONS: Despite the limited sample size, this study demonstrates that the long-term daytime use of sodium oxybate for the treatment of voice symptoms is safe and effective for EtOH+ isolated focal LD patients. The study highlights medical insurance coverage as one of the limiting factors hindering LD patients from accessing this medication.
LEVEL OF EVIDENCE: Level 4.